Profile data is unavailable for this security.
About the company
PeptiDream Inc. is a Japan-based bio-venture company started by the University of Tokyo and principally engaged in the discovery and development of non-standard peptide therapeutics. The Company operates the Peptide Discovery Platform System (PDPS), a drug development platform system and conducts research and development (R&D) on new drug candidates based on the joint R&D with pharmaceutical companies in Japan and overseas. The Company is involved in the business centered on drug development based on special peptides. The Company's businesses include drug discovery joint R&D, PDPS technology loan (PDPS technology license) and expansion of its own pipeline through strategic alliance (strategic alliance or in-house drug discovery).
- Revenue in JPY (TTM)8.33bn
- Net income in JPY2.34bn
- Incorporated2006
- Employees141.00
- LocationPeptiDream Inc3-25-23, Tono-machi, Kawasaki-kuKAWASAKI-SHI 210-0821JapanJPN
- Phone+81 442701300
- Websitehttps://www.peptidream.com/
More ▼
Mergers & acquisitions
| Acquired company | 4587:TYO since announced | Transaction value |
|---|---|---|
| FTP | -61.52% | 184.64m |
Data delayed at least 20 minutes, as of May 27 2022 07:00 BST.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Zeria Pharmaceutical Co Ltd | 59.53bn | 3.96bn | 104.91bn | 1.69k | 22.57 | 1.60 | 11.19 | 1.76 | 87.49 | 87.49 | 1,318.88 | 1,236.09 | 0.4837 | 1.51 | 4.05 | -- | 3.23 | 3.10 | 5.38 | 4.97 | 70.80 | 71.53 | 6.68 | 5.86 | 0.6724 | 21.98 | 0.4867 | 45.54 | 7.38 | -1.70 | 26.97 | 2.25 | -17.52 | 1.81 |
| KYORIN Holdings, Inc. | 105.53bn | 3.93bn | 108.41bn | 2.24k | 24.46 | 0.7723 | 14.18 | 1.03 | 68.60 | 68.60 | 1,841.46 | 2,172.82 | 0.6225 | 1.39 | 2.62 | -- | 2.32 | 3.33 | 2.81 | 4.03 | 46.85 | 51.06 | 3.73 | 5.46 | 2.30 | -- | 0.148 | 67.94 | 2.56 | -1.77 | -35.86 | -11.65 | 0.338 | -2.16 |
| Mochida Pharmaceutical Co., Ltd. | 110.18bn | 10.57bn | 122.49bn | 1.56k | 11.02 | 0.8907 | 9.24 | 1.11 | 276.73 | 276.73 | 2,891.69 | 3,424.21 | 0.6782 | 2.21 | 3.62 | -- | 6.51 | 5.22 | 7.94 | 6.40 | 54.05 | 51.57 | 9.59 | 7.76 | 3.29 | -- | -- | 40.36 | 6.98 | 2.51 | 23.08 | 4.39 | 21.99 | 3.04 |
| Kissei Pharmaceutical Co Ltd | 65.38bn | 12.92bn | 129.32bn | 1.86k | 8.91 | 0.5716 | 7.72 | 1.98 | 280.19 | 280.19 | 1,417.78 | 4,366.96 | 0.2579 | 1.75 | 2.90 | -- | 5.14 | 3.16 | 5.56 | 3.42 | 47.78 | 55.98 | 19.93 | 10.45 | 4.29 | -- | 0.008 | 33.98 | -5.31 | -1.83 | 144.48 | 10.83 | -5.39 | 4.01 |
| KAKEN PHARMACEUTICAL CO., LTD. | 76.03bn | 9.55bn | 164.23bn | 1.22k | 14.24 | 0.9815 | 13.65 | 2.16 | 251.01 | 251.01 | 2,002.07 | 3,642.33 | 0.4629 | 2.28 | 3.73 | -- | 5.81 | 10.15 | 6.64 | 12.06 | 54.68 | 56.09 | 12.56 | 18.28 | 5.02 | -- | 0.0271 | 36.98 | 1.41 | -5.61 | -28.77 | -15.39 | 6.71 | 0.00 |
| Sawai Group Holdings Co Ltd | 193.82bn | -28.27bn | 169.91bn | 3.00k | -- | 0.8939 | -- | 0.8767 | -645.90 | -645.90 | 4,422.78 | 4,340.32 | 0.5218 | 1.54 | 2.87 | -- | -11.29 | 1.25 | -15.50 | 1.70 | 34.39 | 38.97 | -21.63 | 2.46 | 1.31 | -115.52 | 0.2502 | 77.45 | 3.52 | 7.92 | -329.08 | -- | 4.38 | 0.00 |
| Peptidream Inc | 8.33bn | 2.34bn | 205.68bn | 141.00 | 87.85 | 8.32 | 68.48 | 24.70 | 18.01 | 18.01 | 64.02 | 190.06 | 0.2184 | 1.72 | 3.11 | -- | 6.14 | -- | 6.88 | -- | 71.77 | -- | 28.11 | -- | 2.56 | -- | 0.4735 | -- | -19.79 | -- | -18.93 | -- | -- | -- |
| TAKARA BIO INC. | 67.70bn | 19.85bn | 211.81bn | 1.54k | 10.67 | 2.21 | 8.84 | 3.13 | 164.84 | 164.84 | 562.21 | 796.18 | 0.659 | 1.11 | 4.52 | -- | 19.38 | 9.94 | 22.81 | 11.16 | 72.69 | 65.37 | 29.41 | 18.17 | 2.54 | 47.61 | 0.0108 | 21.04 | 46.90 | 18.17 | 107.91 | 71.14 | 52.57 | 52.51 |
| Tsumura & Co | 129.55bn | 18.84bn | 223.14bn | 3.83k | 11.81 | 0.9276 | 7.81 | 1.72 | 246.20 | 246.20 | 1,693.27 | 3,133.96 | 0.3867 | 0.7271 | 2.51 | -- | 5.79 | 5.19 | 7.16 | 6.28 | 51.31 | 56.81 | 14.97 | 12.49 | 2.98 | -- | 0.1614 | 31.77 | -1.02 | 2.42 | 22.85 | 8.57 | 4.99 | 0.00 |
| Hisamitsu Pharmaceutical Co Inc | 120.19bn | 9.66bn | 288.71bn | 2.77k | 28.46 | 1.07 | 20.35 | 2.40 | 119.11 | 119.11 | 1,479.14 | 3,175.01 | 0.3988 | 2.87 | 3.11 | -- | 3.27 | 5.15 | 3.67 | 5.83 | 58.30 | 61.16 | 8.21 | 11.52 | 5.71 | -- | 0.0096 | 44.76 | 4.96 | -3.81 | 4.41 | -13.89 | 5.56 | 0.6061 |
Data as of May 27 2022. Currency figures normalised to PeptiDream Inc's reporting currency: Japanese Yen JPY
23.04%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| JOHCM (Singapore) Pte Ltd.as of 24 Aug 2021 | 5.75m | 4.42% |
| Sumitomo Mitsui Trust Asset Management Co., Ltd.as of 31 Mar 2022 | 4.72m | 3.63% |
| Nomura Asset Management Co., Ltd.as of 31 Mar 2022 | 3.58m | 2.75% |
| Baillie Gifford & Co.as of 31 Mar 2022 | 3.12m | 2.40% |
| Invesco Advisers, Inc.as of 31 Mar 2022 | 3.05m | 2.35% |
| The Vanguard Group, Inc.as of 05 May 2022 | 2.18m | 1.67% |
| Nikko Asset Management Co., Ltd.as of 31 Mar 2022 | 2.01m | 1.55% |
| Shiozumi Asset Management Co. Ltd.as of 31 Mar 2022 | 1.90m | 1.46% |
| BlackRock Fund Advisorsas of 30 Nov 2021 | 1.82m | 1.40% |
| Daiwa Asset Management Co. Ltd.as of 28 Apr 2022 | 1.82m | 1.40% |
More ▼
Data from 30 Sep 2019 - 31 Mar 2022Source: FactSet Research Systems Inc.
